Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine

Am J Physiol Heart Circ Physiol. 2003 Feb;284(2):H519-27. doi: 10.1152/ajpheart.00717.2002. Epub 2002 Sep 19.

Abstract

The relative roles of mitochondrial (mito) ATP-sensitive K(+) (mitoK(ATP)) channels, protein kinase C (PKC), and adenosine kinase (AK) in adenosine-mediated protection were assessed in Langendorff-perfused mouse hearts subjected to 20-min ischemia and 45-min reperfusion. Control hearts recovered 72 +/- 3 mmHg of ventricular pressure (50% preischemia) and released 23 +/- 2 IU/g lactate dehydrogenase (LDH). Adenosine (50 microM) during ischemia-reperfusion improved recovery (149 +/- 8 mmHg) and reduced LDH efflux (5 +/- 1 IU/g). Treatment during ischemia alone was less effective. Treatment with 50 microM diazoxide (mitoK(ATP) opener) during ischemia and reperfusion enhanced recovery and was equally effective during ischemia alone. A(3) agonism [100 nM 2-chloro-N(6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide], A(1) agonism (N(6)-cyclohexyladenosine), and AK inhibition (10 microM iodotubercidin) all reduced necrosis to the same extent as adenosine, but less effectively reduced contractile dysfunction. These responses were abolished by 100 microM 5-hydroxydecanoate (5-HD, mitoK(ATP) channel blocker) or 3 microM chelerythrine (PKC inhibitor). However, the protective effects of adenosine during ischemia-reperfusion were resistant to 5-HD and chelerythrine and only abolished when inhibitors were coinfused with iodotubercidin. Data indicate adenosine-mediated protection via A(1)/A(3) adenosine receptors is mitoK(ATP) channel and PKC dependent, with evidence for a downstream location of PKC. Adenosine provides additional and substantial protection via phosphorylation to 5'-AMP, primarily during reperfusion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / administration & dosage*
  • Adenosine / pharmacology
  • Adenosine Kinase / metabolism
  • Adenosine Triphosphate / metabolism
  • Animals
  • Cardiotonic Agents / administration & dosage*
  • Cardiotonic Agents / pharmacology
  • Diazoxide / pharmacology
  • Drug Administration Schedule
  • In Vitro Techniques
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria, Heart / metabolism
  • Myocardial Ischemia / metabolism
  • Myocardial Ischemia / physiopathology*
  • Myocardial Reperfusion Injury / metabolism
  • Myocardial Reperfusion Injury / physiopathology*
  • Potassium Channels / metabolism
  • Protein Kinase C / metabolism
  • Purinergic P1 Receptor Agonists
  • Recovery of Function

Substances

  • Cardiotonic Agents
  • Potassium Channels
  • Purinergic P1 Receptor Agonists
  • Adenosine Triphosphate
  • Adenosine Kinase
  • Protein Kinase C
  • Adenosine
  • Diazoxide